Volume 5.45 | Nov 14

Mammary Cell News 5.45 November 14, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
Experiments in breast cancer cells indicated constitutive, ligand-independent transcriptional activity of the substitution of aspartic acid at position 538 to glycine (D538G) receptor, and overexpression of it enhanced proliferation and conferred resistance to tamoxifen. [Cancer Res] Abstract
Use Aldefluor to Detect Breast Cancer Stem Cells - Click here to learn more
PUBLICATIONS (Ranked by impact factor of the journal)

Nanoparticle-Directed Sub-Cellular Localization of Doxorubicin and the Sensitization Breast Cancer Cells by Circumventing GST-Mediated Drug Resistance
Researchers demonstrated that polyester-based hyperbranched dendritic-linear-based nanoparticles carrying doxorubicin can effectively overcome microsomal glutathione transferase 1-mediated drug resistance in breast cancer cells. [Biomaterials] Full Article

Lapatinib-Induced NF-KappaB Activation Sensitizes Triple-Negative Breast Cancer Cells to Proteasome Inhibitors
Researchers showed that nuclear factor-kappaB activation was elicited by lapatinib, independent of epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibition, in triple-negative breast cancers. [Breast Cancer Res] Abstract | Full Article

An Investigation of the Effects of the Telomerase Core Protein TERT on Wnt Signaling in Human Breast Cancer Cells
Scientists investigated the effects of hTERT on Wnt signaling in human breast cancer lines and HeLa cells. They failed to find evidence for physical association of hTERT with BRG1 or β-catenin; instead, they present evidence that anti-FLAG antibody cross-reactivity properties may explain the previously reported interaction of hTERT with β-catenin. [Mol Cell Biol] Abstract

Support of a Bi-Faceted Role of ERβ in ERα-Positive Breast Cancer Cells
Researchers explored the functions of constitutively expressed estrogen receptor (ER)β in ERα-positive breast cancer lines MCF7 and T47D. They found that ERβ, under these conditions heterodimerized with ERα in presence and absence of 17β-estradiol, and induced genome-wide transcriptional changes. [Endocr Relat Cancer] Abstract

Receptor Protein Tyrosine Phosphatase α Regulates Focal Adhesion Kinase Phosphorylation and Contributes to ErbB2-Mediated Mammary Epithelial Cell Motility
Scientists investigated the role of PTPα in regulating signaling by the ErbB2 oncoprotein in mammary epithelial cells. Using this model they demonstrated that activation of ErbB2 led to the transient inactivation of PTPα. [J Biol Chem] Abstract

Role of Isothiocyanate Conjugate of Pterostilbene on the Inhibition of MCF-7 Cell Proliferation and Tumor Growth in Ehrlich Ascitic Cell Induced Tumor Bearing Mice
A novel class of hybrid compound synthesized by introducing an ITC moiety on PTER backbone was evaluated for its anti-cancer efficacy in hormone-dependent breast cancer cell line in vitro and Ehrlich ascitic tumor bearing mice model in vivo. [Exp Cell Res] Abstract

MicroRNA-143 Is Downregulated in Breast Cancer and Regulates DNA Methyltransferases 3A in Breast Cancer Cells
Researchers showed that miroRNA (miR)-143 was frequently downregulated in 80% of breast carcinoma tissues compared to their adjacent noncancerous tissues. Ectopic expression of miR-143 inhibited proliferation and soft agar colony formation of breast cancer cells and also downregulated DNA methyltransferase 3A expression on both mRNA and protein levels. [Tumor Biol] Abstract

Cytotoxic Effect of Alpinia scabra (Blume) Naves Extracts on Human Breast and Ovarian Cancer Cells
Crude methanol and fractionated extracts (hexane, chloroform and water) from different parts of A. scabra (leaves, rhizomes, roots and pseudo stems) were prepared prior to cytotoxicity evaluation against human ovarian and hormone-dependent breast carcinoma cells. [BMC Complement Altern Med]
Abstract | Full Article


Fluorouracil, Epirubicin, and Cyclophosphamide (FEC-75) followed by Paclitaxel Plus Trastuzumab versus Paclitaxel Plus Trastuzumab followed by FEC-75 Plus Trastuzumab as Neoadjuvant Treatment for Patients with HER2-Positive Breast Cancer (Z1041): A Randomized, Controlled, Phase III Trial
The authors investigated the effect of the timing of trastuzumab administration with anthracycline and taxane neoadjuvant chemotherapy. This randomized trial was done at 36 centers in the USA and Puerto Rico. [Lancet Oncol] Abstract | Press Release

Gene Aberrations of RRM1 and RRM2B and Outcome of Advanced Breast Cancer after Treatment with Docetaxel With or Without Gemcitabine
The authors retrospectively evaluated whether copy number changes of the genes encoding the ribonucleotide reductase subunit M1 (RRM1) and/or subunit M2B (RRM2B) predict sensitivity to gemcitabine administered in combination with docetaxel compared to single agent docetaxel in advanced breast cancer patients. [BMC Cancer] Abstract | Full Article

Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells
miRNA Dysregulation in Breast Cancer
The authors focus on the area of miRNA dysregulation in breast cancer through both genetic and epigenetic mechanisms, and the impact of this dysregulation on breast cancer risk and resistance to therapies. [Cancer Res] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
UPMC Expands the Use of Next-Generation Sequencing for Cancer Patients to Guide New Therapies
In a move away from a one-size-fits-most approach to treating cancer, University of Pittsburgh Medical Center (UPMC) and the University of Pittsburgh are significantly expanding capabilities to use next-generation sequencing to provide personalized care for cancer patients. The program, initiated a year ago, has completed the analysis of 250 patients with advanced cancer who failed standard therapies, leading to new therapeutic targets and a more dynamic model of care for cancer patients. [University of Pittsburgh Medical Center] Press Release

Heritage-DREAM, National Cancer Institute Breast Cancer Network Inference Challenge Announces Best Performers
Heritage Provider Network, The National Cancer Institute, Sage Bionetworks and DREAM announced the best performers in the Heritage-DREAM Breast Cancer Network Inference Challenge. The competition challenged teams to use big data to develop more effective treatments for breast cancer. [PR Newswire Association LLC] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Keystone Symposia: Stem Cells and Cancer
February 2-7, 2014
Banff, Canada

Visit our events page to see a complete list of events in the mammary cell community.
NEW Assistant, Associate, or Research Professor – Breast Cancer (Indiana University School of Medicine)

Postdoctoral Fellow – Breast Cancer Stem Cell Biology (UC – College of Medicine)

Research Assistant – BREAST-PREDICT (National University of Ireland Galway)

Postdoctoral Position – Breast Cancer Research (Albert Einstein College of Medicine)

Postdoctoral Position – Computational Biology and Cancer Genomics (Albert Einstein College of Medicine)

Postdoctoral Position – Computational Biology of Cancer (Gustave Roussy Cancer Institute)

PhD Position – Breast Cancer Bone Metastasis Formation (Claude Bernard University Lyon 1)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Mammary Cell News: Archives | Events | Contact Us